CL2021003134A1 - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos - Google Patents
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestosInfo
- Publication number
- CL2021003134A1 CL2021003134A1 CL2021003134A CL2021003134A CL2021003134A1 CL 2021003134 A1 CL2021003134 A1 CL 2021003134A1 CL 2021003134 A CL2021003134 A CL 2021003134A CL 2021003134 A CL2021003134 A CL 2021003134A CL 2021003134 A1 CL2021003134 A1 CL 2021003134A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- isoindoline
- oxo
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855619P | 2019-05-31 | 2019-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003134A1 true CL2021003134A1 (es) | 2022-07-01 |
Family
ID=73551319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003134A CL2021003134A1 (es) | 2019-05-31 | 2021-11-24 | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11306101B2 (enExample) |
| EP (1) | EP3976595A4 (enExample) |
| JP (2) | JP7496838B2 (enExample) |
| KR (2) | KR102913106B1 (enExample) |
| CN (4) | CN114957212B (enExample) |
| AR (1) | AR119057A1 (enExample) |
| AU (1) | AU2020282748A1 (enExample) |
| BR (1) | BR112021022758A2 (enExample) |
| CA (1) | CA3136753A1 (enExample) |
| CL (1) | CL2021003134A1 (enExample) |
| CO (1) | CO2021015624A2 (enExample) |
| IL (1) | IL288278B2 (enExample) |
| MX (1) | MX2021014350A (enExample) |
| MY (1) | MY208545A (enExample) |
| PE (1) | PE20220569A1 (enExample) |
| SG (1) | SG11202112872YA (enExample) |
| TW (2) | TWI851729B (enExample) |
| WO (1) | WO2020243379A1 (enExample) |
| ZA (1) | ZA202109003B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102913106B1 (ko) | 2019-05-31 | 2026-01-19 | 셀진 코포레이션 | 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| MX2023004374A (es) * | 2020-10-14 | 2023-07-06 | C4 Therapeutics Inc | Ligandos tricíclicos para la degradación de la familia ikaros 2 o la familia ikaros 4. |
| CN112679421A (zh) * | 2021-01-04 | 2021-04-20 | 都创(上海)医药科技股份有限公司 | 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN118019534A (zh) * | 2021-05-06 | 2024-05-10 | 细胞基因公司 | 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法 |
| CA3221549A1 (en) * | 2021-06-08 | 2022-12-15 | Liqiang Fu | Isoindolinone compounds, and uses thereof |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4540240A1 (en) * | 2022-06-16 | 2025-04-23 | Monte Rosa Therapeutics AG | Molecular glue degraders and methods of using the same |
| EP4540238A1 (en) * | 2022-06-16 | 2025-04-23 | Monte Rosa Therapeutics AG | Molecular glue degraders and methods of using the same |
| WO2024027694A1 (zh) * | 2022-08-01 | 2024-02-08 | 苏州开拓药业股份有限公司 | 一种蛋白降解剂 |
| JP2025541841A (ja) * | 2022-12-07 | 2025-12-23 | ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド | オキソイソインドール－５－カルボキサミド系化合物またはその塩、溶媒和物の結晶形または無定形 |
| JP2025541840A (ja) * | 2022-12-07 | 2025-12-23 | ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド | 固体分散体、その製造方法と使用 |
| PL249026B1 (pl) * | 2022-12-09 | 2026-02-23 | Univ Mikolaja Kopernika W Toruniu | Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| UA91560C2 (ru) | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ZA200901078B (en) * | 2006-08-30 | 2010-06-30 | Celgene Corp | 5-substituted isoindoline compounds |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| KR102913106B1 (ko) | 2019-05-31 | 2026-01-19 | 셀진 코포레이션 | 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
-
2020
- 2020-05-29 KR KR1020217042866A patent/KR102913106B1/ko active Active
- 2020-05-29 CA CA3136753A patent/CA3136753A1/en active Pending
- 2020-05-29 SG SG11202112872YA patent/SG11202112872YA/en unknown
- 2020-05-29 KR KR1020257017146A patent/KR20250078628A/ko active Pending
- 2020-05-29 MY MYPI2021006946A patent/MY208545A/en unknown
- 2020-05-29 TW TW109117973A patent/TWI851729B/zh active
- 2020-05-29 US US16/887,766 patent/US11306101B2/en active Active
- 2020-05-29 PE PE2021001963A patent/PE20220569A1/es unknown
- 2020-05-29 AU AU2020282748A patent/AU2020282748A1/en not_active Abandoned
- 2020-05-29 CN CN202210612012.4A patent/CN114957212B/zh active Active
- 2020-05-29 BR BR112021022758A patent/BR112021022758A2/pt unknown
- 2020-05-29 JP JP2021570866A patent/JP7496838B2/ja active Active
- 2020-05-29 CN CN202080040212.6A patent/CN114269729B/zh active Active
- 2020-05-29 AR ARP200101539A patent/AR119057A1/es unknown
- 2020-05-29 CN CN202510008872.0A patent/CN119930578A/zh active Pending
- 2020-05-29 IL IL288278A patent/IL288278B2/en unknown
- 2020-05-29 TW TW113131211A patent/TW202523657A/zh unknown
- 2020-05-29 MX MX2021014350A patent/MX2021014350A/es unknown
- 2020-05-29 EP EP20812650.8A patent/EP3976595A4/en active Pending
- 2020-05-29 CN CN202410679319.5A patent/CN118724867A/zh active Pending
- 2020-05-29 WO PCT/US2020/035043 patent/WO2020243379A1/en not_active Ceased
-
2021
- 2021-11-12 ZA ZA2021/09003A patent/ZA202109003B/en unknown
- 2021-11-22 CO CONC2021/0015624A patent/CO2021015624A2/es unknown
- 2021-11-24 CL CL2021003134A patent/CL2021003134A1/es unknown
-
2022
- 2022-03-09 US US17/690,921 patent/US12486281B2/en active Active
-
2024
- 2024-05-28 JP JP2024086242A patent/JP2024123001A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003134A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| CO2021007973A2 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos | |
| CO2022018653A2 (es) | Compuestos de unión a cereblón, composiciones de estos y métodos de tratamiento con estos | |
| CL2019003800A1 (es) | Métodos para tratar la enfermedad de huntington. | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| NI201300113A (es) | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas. | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| ECSP22012650A (es) | Composiciones que comprenden tigolaner para el control de parásitos | |
| MX2020003554A (es) | Moduladores de la expresion de enac. | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| BR112021018266A2 (pt) | Composições e métodos para tratar formas positivas de receptor andrógeno de câncer | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 |